Somnair Secures $4.3M Seed Funding for Innovative Sleep Apnea Device Development

Somnair, a Towson, Md.-based startup founded by Johns Hopkins alumni, has successfully raised $4.3 million in a seed funding round to advance the development of its innovative device designed to manage obstructive sleep apnea. This financial milestone was disclosed through an SEC filing, although the investors were not named. The co-founders, all graduates of the Johns Hopkins Whiting School of Engineering’s Biodesign program, bring a diverse set of skills and experiences to the venture, aiming to address a critical gap in sleep apnea treatment.

Obstructive sleep apnea affects an estimated 54 million Americans, disrupting their breathing during sleep and increasing the risk of chronic conditions such as heart disease and diabetes. Current treatments, primarily CPAP machines, are often abandoned by patients due to discomfort and high costs. Somnair’s device, which is non-invasive and worn in the mouth like a retainer, targets the root cause of the condition by stimulating a specific nerve to help open the airway, offering a promising alternative for those unable to tolerate existing treatments.

The startup’s approach was inspired by extensive research and observation, including shadowing ENT surgeons and engaging with patients who found CPAP therapy unsuitable. Early results from a proof-of-concept study involving 22 patients have been encouraging, validating the team’s hypothesis that their device can effectively open airways in individuals who cannot use CPAP. With MedStar Health as an early backer, Somnair is poised to make significant strides in sleep apnea treatment, potentially improving the quality of life for millions.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Somnair Secures $4.3M Seed Funding for Innovative Sleep Apnea Device Development.